Thromboembolism and Bleeding in Newly Diagnosed Multiple Myeloma – Rates, Risk Profile and Patterns of Thromboprophylaxis

Introduction Patients with multiple myeloma (MM) treated with immunomodulatory drugs (IMiDs) have a high risk of venous thromboembolisms (VTE). Guidelines suggest pharmacological thromboprophylaxis in all patients treated with IMiD-based regimens, using aspirin for patients at low, and low molecular weight heparin (LMWH) or vitamin K antagonists (VKA) for those at high VTE risk. Direct oral anticoagulants (DOACs) have not yet been sufficiently studied in this indication but could be an effective and convenient alternative and have since 2012 been offered as such at our centre.